Fed’s Powell opens door to potential rate cuts at Jackson Hole
AMSTERDAM—uniQure N.V. (NASDAQ:QURE) CEO and Managing Director Matthew Kapusta recently executed a series of transactions involving the company’s ordinary shares, according to a regulatory filing. On March 4, Kapusta sold 28,341 shares of uniQure at an average price of $10.29 per share, totaling $291,628. The shares were sold to cover estimated withholding taxes upon the vesting of restricted share units, as per the automatic sale instructions in the relevant agreement. The transaction comes as uniQure’s stock, currently trading at $12.09, has shown significant volatility, with a remarkable 118% gain over the past six months despite being down 31% year-to-date. InvestingPro analysis indicates the stock is currently fairly valued based on its proprietary Fair Value model.
Additionally, Kapusta acquired 99,000 ordinary shares on March 3 at no cost, as part of a grant under the company’s 2014 Share Incentive Plan. These restricted share units vest in equal annual installments over three years. Furthermore, Kapusta also received stock options for 171,000 shares, which vest over a four-year period, starting with 25% on the first anniversary of the grant date. The biotech company, with a market capitalization of $650 million, maintains strong liquidity with a current ratio of 9.74, though InvestingPro data shows it faces profitability challenges with negative earnings per share of $4.92 in the last twelve months.
Following these transactions, Kapusta holds 651,454 shares directly. The company’s stock trades with an average daily volume of 2.31 million shares and currently sits well above its 52-week low of $3.73, though still below its high of $19.18.
In other recent news, uniQure has announced the pricing of its public offering of 4,411,764 ordinary shares at $17.00 each, with expectations to raise approximately $75 million before deductions. The offering is expected to close around January 10, 2025, subject to customary conditions. Meanwhile, H.C. Wainwright reaffirmed its Buy rating on uniQure, setting a price target of $70, citing optimism about the company’s gene therapy pipeline, particularly the AMT-130 program for Huntington’s disease. The firm’s analysts highlighted the potential impact of upcoming regulatory updates and pivotal data expected in 2025. uniQure has also completed enrollment for the first cohort in a Phase I/IIa trial of AMT-191, a gene therapy for Fabry disease, with no significant safety concerns reported. The U.S. FDA has granted AMT-191 Orphan Drug status and Fast Track designation, acknowledging the treatment’s potential for rare diseases. In related developments, CSL (OTC:CSLLY) Behring confirmed the long-term efficacy of HEMGENIX, a hemophilia B treatment originally developed by uniQure. The four-year results from the HOPE-B study demonstrated sustained factor IX activity levels and a reduction in annualized bleeding rates. These recent developments underscore uniQure’s ongoing advancements in gene therapy treatments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.